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Introduction
An urachus is a midline embryonic remnant structure within the space of Retzius that extends 
superiorly from the anterior bladder dome toward the umbilicus. Prior to birth, the urachus 
involutes to become the median umbilical ligament. Failure to regress can lead to various congenital 
anomalies. In a minority of cases, urachal tract remnants undergo malignant transformation to 
urachal cancer, a very rare cancer that represents 0.5% of bladder malignancies; of these, 85-90% 
is adenocarcinomas [1]. Urachal adenocarcinomas have a 2:1 male predominance, and patients 
typically present in midlife [1].
Urachal adenocarcinomas arise from metaplasia of urachal epithelium with subsequent 
malignant transformation [1]. While there are multiple histological subtypes, 75-90% of these 
tumors are mucin-secreting [1]. Due to their extraperitoneal location, these tumors tend to be 
clinically silent for much of their course. When present, the most common manifestation is gross 
hematuria. Prognosis is dependent on surgical margins and stage with the latter based on criteria set 
forth by Sheldon et al. [2] (Table 1). More broadly, prognosis is relatively poor, as patients tend to 
present later in the disease course [3].
The mainstay of treatment is a partial cystectomy with en-bloc resection of the umbilicus 
and urachal ligament with bilateral pelvic lymphadenectomy. While there is no definitive role for 
neoadjuvant or adjuvant chemotherapy, there is some evidence that 5-FU and cisplatin combinations 
may be helpful under special circumstances [3].
Imaging plays an increasingly large role in diagnosis and staging. Due to the rarity of urachal 
adenocarcinomas, however, literature documenting characteristic imaging findings is limited. This 
case report will highlight these imaging findings.
Case Presentation
A 43-year old male initially presented to an outside institution with gross hematuria, fatigue, 
and dysuria. Physical examination was unremarkable, and urinalysis showed trace hematuria. 
CT urogram showed a 3.4 cm x 2.9 cm peripherally calcified mass located superior to the bladder 
dome without any significant enhancement. No suspicious lymphadenopathy or bony lesions were 
noted. Cystoscopy was performed, showing a 2 cm mass near the bladder dome with calcification 
and necrotic tissue consistent with malignancy. Pathologic results suggested transitional cell 
adenocarcinoma.
Given the tumor’s location, this diagnosis was questioned, and reevaluation at our institution 
suggested urachal adenocarcinoma. Repeat cystoscopy with mass and random bladder biopsies was 
negative for any urothelial adenocarcinoma, consistent with urachal adenocarcinomas. [18F]FDG 
PET showed no significant hypermetabolic activity within the bladder mass.
The patient underwent robotic-assisted laparoscopic partial cystectomy, umbilectomy, 
and bilateral pelvic lymph node dissection. A 3.5 cm mass was resected from the bladder dome; 
pathologic studies confirmed a high-grade mucin-producing urachal adenocarcinoma of signet cell 
type. Surgical margins and biopsied lymph nodes were negative, staging the tumor at T3aN0M0. 
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Abstract
As urachal adenocarcinomas are rare cancers, experience with diagnosing and staging them are 
limited. To help illustrate CT and PET imaging findings and the role they each play in the workup of 
urachal adenocarcinomas, we present the case of a 43 y.o. male who was diagnosed at our institution 
with a T3aN0M0 high grade mucin-producing urachal adenocarcinoma.
Merissa Zeman, Ethan Silver and Esma Akin*
Department of Radiology, George Washington University Hospital, USA
Esma Akin, et al., Annals of Clinical Case Reports - Oncology
Remedy Publications LLC., | http://anncaserep.com/ 2017 | Volume 2 | Article 12522
The patient underwent adjuvant chemotherapy with four cycles of 
fluorouracil, gemcitabine, and cisplatin. To date, there has been no 
evidence of residual or recurrent tumor (Figure 1).
Discussion
Despite there being no consensus regarding diagnostic criteria 
for urachal adenocarcinomas, there are certain features that are 
highly suggestive of their diagnosis, including: tumor location in the 
bladder wall or dome; sharp demarcation between tumor and surface 
bladder epithelium; and exclusion of primary adenocarcinomas 
in another location [4]. While these criteria are useful in defining 
urachal adenocarcinomas, their clinical utility can be improved with 
the inclusion of comprehensive imaging findings, as most patients are 
likely to undergo imaging as part of their work-up. The intent of this 
case report is to showcase these findings.
CT is the most widely used imaging modality to diagnose and 
stage urachal tumors. CT findings most characteristic of these tumors 
include: A) an anterior supravesical midline mass in the space of 
Retzius; B) heterogeneous enhancement with areas of low attenuation; 
and C) peripheral calcifications in the mass [5]. The presence of all 
three findings is pathognomonic. 
Unlike with CT, there are no pathognomonic PET findings. 
Rather, these tumors demonstrate considerable variation in their 
degree of hypermetabolism [6,7]. For example, this case yielded a 
false-negative PET scan. The failure of PET to detect this patient’s 
malignancy is not unexpected in the context of the tumor’s mucinous 
pathology, a characteristic of 75-90% of urachal adenocarcinomas 
[1]. It is well documented that mucinous adenocarcinomas are not as 
[18F]FDG-avid as non-mucinous ones [8]. The abundant mucin that 
they produce limits their cellularity, and thus, [18F]FDG uptake [8]. 
While there are no studies that specifically address the avidity of [18F]
FDG uptake in mucinous urachal adenocarcinomas, this limitation 
observed for other mucinous tumors likely applies to those of urachal 
origin. 
Furthermore, this patient’s tumor exhibits a central, unilocular 
mucin distribution, restricting the thickness of the tumor’s walls. If 
this thickness falls below the spatial resolution of the PET scanner, 
there is loss of measured activity secondary to the partial-volume 
effect. Additionally, irrespective of the tumor’s mucin production, 
the activity of urachal adenocarcinomas and their progression into 
adjacent structures can be difficult to evaluate due to their proximity 
to the bladder, which appears hypermetabolic on PET secondary to 
urinary [18F]FDG excretion.
As exemplified by this case, urachal adenocarcinomas have a 
high potential to be PET negative. Consequently, PET’s role in their 
work-up is limited. But, as not all urachal adenocarcinomas are 
PET negative, PET has some utility in their work-up. Various cases 
have reported mild or moderate [18F]FDG uptake for these tumors 
[6,7]. Visual inspection of these cases suggests that patients with 
metastatic disease and/or tumors with greater solid composition 
are more likely to have elevated [18F]FDG uptake. This patient’s 
tumor, in comparison, is not metastatic and does not exhibit a high 
solid composition, making [18F]FDG uptake unlikely. While more 
information is needed, it is reasonable for physicians to assess for 
the presence/absence of these two variables and use this information 
to help guide decision-making on the appropriateness of obtaining 
PET in the work-up of urachal adenocarcinoma. For example, if a 
patient’s CT shows urachal tumor with a significant solid component, 
obtaining a PET scan is reasonable.
Altogether, due to the high likelihood of false negative results, 
PET imaging has an adjunct role in the work-up of urachal 
adenocarcinomas. Rather, CT, with its pathognomonic findings, is 
the modality of choice for these tumors.
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Stage I: No invasion beyond the urachal mucosa
Stage II: Invasion confined to the urachus




Viscera other than the bladder (IIID)
Stage IV: Metastases to the:
Regional lymph nodes (IVA)
Distant sites (IVB)
Table 1: Sheldon Staging System for Urachal Carcinoma.
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Figure 1: (a) Fused axial PET-CT slice showing peripherally calcified 
urachal mass with minimal metabolic activity, isointense to background. (b 
& c) non contrast enhanced CT slices in the same area showing the low 
density urachal mass with peripheral stippled appearing calcifications. (d) 
PET only image showing minimal to no discernable metabolic activity within 
the urachal mass.
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